Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Aug 5:3:405.
doi: 10.1186/2193-1801-3-405. eCollection 2014.

Is radiotherapy necessary for intermediate risk ductal carcinoma in situ after breast conserving surgery?

Affiliations

Is radiotherapy necessary for intermediate risk ductal carcinoma in situ after breast conserving surgery?

Taeryung Kim et al. Springerplus. .

Abstract

Identifying ductal carcinoma in situ (DCIS) patients at highest risk for recurrence after breast conserving surgery (BCS) remains a clinical concern. Subjecting all such patients to radiotherapy may be unnecessary. The Van Nuys Prognostic Index (VNPI) is a simple scoring system for predicting the risk of local recurrence in patients with DCIS. We reviewed patients with DCIS applying the VNPI score system. A total of 184 DCIS patients who underwent surgery at our institution between January 2003 and December 2011 were identified. Patients were not treated according to VNPI guidelines; rather, radiation therapy was applied at each surgeon's discretion. All patients with hormonal receptor positive tumors were treated with hormonal therapy. Pathology reports were reviewed and VNPI scores of each DCIS calculated. Of the 184 patients, 52 (28.3%), 115 (62.5%) and 17 (9.2%) had low, intermediate and high VNPI scores, respectively. Six of the 184 patients (3.3%) developed ipsilateral local recurrence, five in the intermediate and one in the high VNPI score group. Of the five in the intermediate group, three (60%) were in patients with ER-negative tumors. VNPI score itself was not associated with recurrence (P = 0.145). Factors associated with recurrence included tumor size (hazard ratio [HR] 6.88), grade (HR 9.07) and hormone receptor status (HR 11.75). Radiotherapy did not significantly improve recurrence rates in patients with low and intermediate risk DCIS, especially in those with ER-positive tumors. Radiotherapy can be omitted in patients with ER-positive intermediate score DCIS and in patients with low score DCIS.

Keywords: Breast cancer; Ductal carcinoma in situ; ER; Radiotherapy; Recurrence; Van Nuys Prognostic index.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Ipsilateral breast tumor recurrence (IBTR)-free survival.
Figure 2
Figure 2
Ipsilateral breast tumor recurrence(IBTR)-free survival. (a) IBTR-free survival according to age (b) IBTR-free survival according to margin width (c) IBTR-free survival according to VNPI score.

Similar articles

Cited by

References

    1. Allegra CJ, Aberle DR, Ganschow P, Hahn SM, Lee CN, Millon-Underwood S, Pike MC, Reed SD, Saftlas AF, Scarvalone SA, Schwartz AM, Slomski C, Yothers G, Zon R. National Institutes of Health State-of-the-Science Conference statement: diagnosis and management of ductal carcinoma in situ September 22–24, 2009. J Natl Cancer Inst. 2010;102(3):161–169. doi: 10.1093/jnci/djp485. - DOI - PubMed
    1. Altintas S, Toussaint J, Durbecq V, Lambein K, Huizing MT, Larsimont D, Van Marck E, Vermorken JB, Tjalma WA, Sotiriou C. Fine tuning of the Van Nuys prognostic index (VNPI) 2003 by integrating the genomic grade index (GGI): new tools for ductal carcinoma in situ (DCIS) Breast J. 2011;17(4):343–351. doi: 10.1111/j.1524-4741.2011.01091.x. - DOI - PubMed
    1. Asjoe FT, Altintas S, Huizing MT, Colpaert C, Marck EV, Vermorken JB, Tjalma WA. The value of the Van Nuys Prognostic Index in ductal carcinoma in situ of the breast: a retrospective analysis. Breast J. 2007;13(4):359–367. doi: 10.1111/j.1524-4741.2007.00443.x. - DOI - PubMed
    1. Baird RM, Worth A, Hislop G. Recurrence after lumpectomy for comedo-type intraductal carcinoma of the breast. Am J Surg. 1990;159(5):479–481. doi: 10.1016/S0002-9610(05)81250-4. - DOI - PubMed
    1. Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res. 2005;11(6):2163–2168. doi: 10.1158/1078-0432.CCR-04-1633. - DOI - PubMed

LinkOut - more resources